Adaptive Biotechnologies (ADPT)
(Real Time Quote from BATS)
$2.76 USD
+0.16 (6.15%)
Updated Apr 29, 2024 02:46 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Balance Sheet
Fiscal Year End for Adaptive Biotechnologies Corporation falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 346 | 498 | 353 | 688 | 577 |
Receivables | 38 | 40 | 17 | 10 | 13 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 14 | 14 | 19 | 14 | 9 |
Other Current Assets | 11 | 9 | 13 | 15 | 14 |
Total Current Assets | 410 | 562 | 403 | 727 | 613 |
Net Property & Equipment | 68 | 83 | 85 | 40 | 60 |
Investments & Advances | 0 | 0 | 217 | 119 | 105 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 124 | 126 | 128 | 129 | 131 |
Deposits & Other Assets | 7 | 4 | 3 | 3 | 3 |
Total Assets | 661 | 857 | 923 | 1,116 | 912 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 8 | 8 | 3 | 3 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 22 | 28 | 25 | 25 | 13 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 49 | 64 | 80 | 73 | 61 |
Total Current Liabilities | 88 | 110 | 114 | 105 | 78 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 45 | 59 | 99 | 164 | 226 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 37 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 131 | 125 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 353 | 393 | 319 | 373 | 341 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,453 | 1,387 | 1,324 | 1,254 | 936 |
Retained Earnings | -1,144 | -919 | -719 | -512 | -365 |
Other Equity | 0 | -4 | -1 | 1 | 1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 308 | 464 | 604 | 743 | 571 |
Total Liabilities & Shareholder's Equity | 661 | 857 | 923 | 1,116 | 912 |
Total Common Equity | 308 | 464 | 604 | 743 | 571 |
Shares Outstanding | 144.70 | 143.00 | 141.10 | 136.70 | 124.30 |
Book Value Per Share | 2.13 | 3.25 | 4.28 | 5.44 | 4.59 |
Fiscal Year End for Adaptive Biotechnologies Corporation falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 346 | 371 | 417 | 441 |
Receivables | NA | 38 | 31 | 32 | 31 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 14 | 19 | 19 | 20 |
Other Current Assets | NA | 11 | 13 | 9 | 10 |
Total Current Assets | NA | 410 | 435 | 477 | 501 |
Net Property & Equipment | NA | 68 | 77 | 79 | 81 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 124 | 125 | 125 | 125 |
Deposits & Other Assets | NA | 7 | 6 | 6 | 5 |
Total Assets | NA | 661 | 718 | 765 | 791 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 8 | 4 | 9 | 6 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 22 | 21 | 19 | 14 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 49 | 59 | 58 | 60 |
Total Current Liabilities | NA | 88 | 93 | 95 | 90 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 45 | 44 | 51 | 54 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 127 | 128 | 127 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 353 | 356 | 369 | 368 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 1,453 | 1,437 | 1,422 | 1,403 |
Retained Earnings | NA | -1,144 | -1,075 | -1,025 | -977 |
Other Equity | NA | 0 | 0 | -1 | -2 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 308 | 362 | 396 | 424 |
Total Liabilities & Shareholder's Equity | NA | 661 | 718 | 765 | 791 |
Total Common Equity | 0 | 308 | 362 | 396 | 424 |
Shares Outstanding | 145.00 | 144.70 | 144.60 | 144.60 | 144.30 |
Book Value Per Share | 0.00 | 2.13 | 2.50 | 2.74 | 2.94 |